Frisch, E. P.; Blombäck, M.; Ekeström, S.; Kiessling, H.; Lund, F.; Magaard, F.
July 1975
Angiology;Jul/Aug1975, Vol. 26 Issue 7, p557
Academic Journal
In 17 patients a total of 148 brinase infusions were given. All patients but two had anticoagulant treatment (dicoumarol or heparin) during the brinase series. Dosage of brinase was based on determination of brinase inhibitor capacity in plasma (azocollagen technique) prior to infusion of the enzyme. Iv infusion of brinase lowered inhibitors in plasma. Good correlation was found between expected lowering and measured inhibitor values after brinase infusion. The stipulated safety margin for brinase inhibitor capacity could be maintained, α1-antitrypsin showed irregular changes and α2-macroglobulin values were decreased by iv infusions of brinase. Fibrinogen values were somewhat lowered after iv brinase infusion. Values for fibrinogen degradation products increased and the ethanol gelation test became positive. Thrombotest values were lowered and the activated partial tbromboplastin time was prolonged in patients receiving dicoumarol and iv heparin respectively. Changes in other coagulation parameters were insignificant. In two patients transient renal failure was recorded, laboratory data indicated intravascular coagulation as a possible cause. None of these two patients were on anticoagulant treatment. One patient developed a haematoma of the forefoot during massive iv heparin treatment during a series of iv infusions of brinase. Bleeding complications due to brinase treatment were not observed.


Related Articles

  • Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Joannidis, Michael; Kountchev, Jordan; Rauchenzauner, Markus; Schusterschitz, Nicola; Ulmer, Hanno; Mayr, Andreas; Bellmann, Romuald // Intensive Care Medicine;Sep2007, Vol. 33 Issue 9, p1571 

    Objective: The purpose of this study was to evaluate the efficacy and safety of the low molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous hemofiltration (CVVH) compared with unfractionated heparin.Design: Prospective randomized controlled...

  • HEPARINE EVALUATION. Trethewie, E. R.; Melvin, P. A. // Australian Journal of Experimental Biology & Medical Science;Sep1945, Vol. 23 Issue 3, p241 

    A method for determining heparine content of solutions from 0.00--0.08 mg. (Kahlbaum) per c.c. has been evolved by modifying the Toluidin Blue method of Copley and Whitney.

  • Antithrombotic activity of heparin-ATP complex. T. Obergan; L. Lyapina; V. Pastorova // Bulletin of Experimental Biology & Medicine;Mar2007, Vol. 143 Issue 3, p299 

    Abstract  The complex of high-molecular-weight heparin and ATP prevented thrombus formation in the blood flow. Repeated intramuscular injection of the complex increased total fibrinolytic activity of the blood, nonenzymatic fibrinolysis, and plasma anticoagulant activity and significantly...

  • Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Jiayin Wang; Noriyuki Ohara; Shigeki Takekida; Qin Xu; Takeshi Maruo // Human Reproduction;Jun2005, Vol. 20 Issue 6, p1456 

    BACKGROUND: The objective of this study was to investigate the comparative effects of heparin-binding epidermal growth factor-like growth factor (HB-EGF) on the growth of cultured human leiomyoma cells and myometrial cells. METHODS: Isolated cells were subcultured in Phenol Red-free Dulbecco''s...

  • Combination of site-directed mutagenesis and calcium ion addition for enhanced production of thermostable MBP-fused heparinase I in recombinant Escherichia coli. Chen, Shuo; Huang, Ziliang; Wu, Jingjun; Chen, Yin; Ye, Fengchun; Zhang, Chong; Yatsunami, Rie; Nakamura, Satoshi; Xing, Xin-Hui // Applied Microbiology & Biotechnology;Apr2013, Vol. 97 Issue 7, p2907 

    Heparinase I (HepI), which specifically cleaves heparin and heparan sulfate, is one of the most extensively studied glycosaminoglycan lyases. Low productivity of HepI has largely hindered its industrial and pharmaceutical applications. Loss of bacterial HepI enzyme activity through poor...

  • Trials That Matter: Can Patients with Venous Thromboembolism Be Treated with Fixed-Dose Subcutaneous Unfractionated Heparin? Goldhaber, Samuel Z.; Berkwits, Michael // Annals of Internal Medicine;12/19/2006, Vol. 145 Issue 12, p929 

    The article focuses on issues related to the safety and efficacy of subcutaneous unfractionated heparin (UFH) relative to low-molecular-weight heparin for treatment of acute venous thromboembolism. According to high-quality research, low-molecular-weight heparin is an efficient alternative to...

  • Use of newer anticoagulants in patients with chronic kidney disease. Lobo, Bob L. // American Journal of Health-System Pharmacy;10/1/2007, Vol. 64 Issue 19, p2017 

    Purpose. The current indications, dosing, and practical considerations for use of newer anticoagulants in patients with various degrees of renal impairment who do not require dialysis are reviewed. Summary. Kidney function should generally be evaluated in all patients commencing anticoagulant...

  • DOSING CONVERSION FOR ANTICOAGULANTS: DABIGATRAN/HEPARIN/WARFARIN.  // Monthly Prescribing Reference;Aug2012, Vol. 28 Issue 8, p58 

    The article offers information on the dosing conversion for anticoagulant medications. It mentions the importance of adjusting the starting time of warfarin basing from the creatinine clearance when one switch from dabigatran to warfarin. It notes that warfarin can be overlapped with full dose...

  • heparin.  // Davis's Drug Guide for Nurses, 9th edition;2005, p492 

    Provides information on heparin, an anticoagulant used for the treatment of various thromboembolic disorders. Pharmacokinetics; Contraindications and precautions; Adverse reactions and side effects; Prescribed dosage.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics